Mark Ragosa Sells 19,900 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 19,900 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $40.94, for a total value of $814,706.00. Following the transaction, the chief financial officer owned 31,086 shares of the company’s stock, valued at approximately $1,272,660.84. This trade represents a 39.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Mark Ragosa also recently made the following trade(s):

• On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.00, for a total value of $4,100.00.

Kiniksa Pharmaceuticals International Stock Up 0.1%

Shares of NASDAQ:KNSA traded up $0.03 during mid-day trading on Friday, reaching $40.32. 264,948 shares of the stock were exchanged, compared to its average volume of 622,492. The company has a market cap of $3.06 billion, a P/E ratio of 89.60 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $42.05. The stock’s 50 day simple moving average is $37.85 and its 200-day simple moving average is $32.23.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. The company’s revenue was up 61.2% on a year-over-year basis. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KNSA. Cerity Partners LLC lifted its holdings in Kiniksa Pharmaceuticals International by 42.3% during the 1st quarter. Cerity Partners LLC now owns 40,708 shares of the company’s stock valued at $904,000 after purchasing an additional 12,110 shares during the last quarter. CWM LLC raised its position in shares of Kiniksa Pharmaceuticals International by 867.4% in the first quarter. CWM LLC now owns 22,114 shares of the company’s stock valued at $491,000 after purchasing an additional 19,828 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $1,184,000. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 62,624 shares of the company’s stock worth $1,391,000 after buying an additional 1,658 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 4.0% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company’s stock worth $326,000 after buying an additional 568 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on KNSA shares. Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Wedbush restated an “outperform” rating and set a $48.00 price objective (up from $44.00) on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, October 28th. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Finally, Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and an average target price of $52.00.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.